J 2015

Can Biomarkers Help to Diagnose Early Heart Failure with Preserved Ejection Fraction?

MELUZÍN, Jaroslav a Josef TOMANDL

Základní údaje

Originální název

Can Biomarkers Help to Diagnose Early Heart Failure with Preserved Ejection Fraction?

Autoři

Vydání

Disease Markers, New York, Hindawi Publishing Corporation, 2015, 0278-0240

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.137

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00082909

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

EID Scopus

Klíčová slova anglicky

Biomarkers; Heart Failure

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 19. 5. 2015 16:13, Soňa Böhmová

Anotace

V originále

Early heart failure with preserved ejection fraction (HFpEF) is a frequent disease, but its diagnosis is difficult and relies mostly on the evidence of left ventricular filling pressure (LVFP) elevation during exercise. Several reports have suggested that natriuretic peptides plasma levels reflect exercise-induced increase in LVFP, but they still have significant limitations. In this context, any new laboratory biomarker that can accurately reflect LVFP elevation during exercise is desirable. Recently, cardiotrophin-1, soluble endoglin, ST2, growth differentiation factor 15, galectin-3, and other new laboratory markers associated with LVFP have emerged. However, the current data on the relationship of these biomarkers and diastolic dysfunction are limited to resting conditions. Therefore, their secretion deserves to be tested under the exercise to determine their potential role in making a diagnosis of early HFpEF.